Hemostatic alterations in cancer patients
- 180 Downloads
Nearly all patients with cancer manifest laboratory evidence of hypercoagulability and some develop clinical thromboembolic disease (TED). Routine laboratory studies of blood coagulation have been performed in several large, prospective trials of the use of anticoagulant drugs in cancer treatment. The results of these studies, as well as data from several smaller studies of more sensitive tests of hypercoagulability [e.g. fibrinopeptide A (FPA); thrombin-antithrombin (TAT) complexes; prothrombin fragment F1+2)], indicate that the levels of some clotting proteins parallel disease activity. However, no studies of sound methodologic design have yet been performed to indicate that any of these tests of blood coagulation can serve as adequate predictors of TED in patients with cancer.
In addition to the important role played by tumor-related procoagulants, several other mechanisms may be involved in the pathogenesis of thromboembolic events in patients with cancer, including stasis and endothelial damage. Considerable variability in the relative importance of these mechanisms in the pathogenesis of TED may exist among patients with different types of cancer.
The risk for TED associated with surgical procedures in cancer patients is substantial and prophylactic antithrombotic therapy should be considered for most of these patients. Chemotherapy and hormonal therapy of cancer probably increases the likelihood of TED, particularly in those subjects with indwelling venous catheters. This risk has been particularly well-studied in patients with breast cancer treated with tamoxifen plus cytotoxic drugs. The pathogenic mechanisms may be complex but vascular injury is likely as a proximate cause of venous access catheter thrombosis and can be prevented with low dose coumadin therapy. The utility of low dose coumadin anticoagulation in reducing the risk for TED during breast cancer treatment is unknown but is currently being tested in a large, multiinstitutional study. Since chronic coumadin anticoagulation of cancer patients, and single pulse dose heparin prior to intravenous chemotherapy, both prevent thrombin generation, these agents may be of use in reducing the risk of chemotherapy-associated thrombosis. Prophylactic anticoagulation should be considered for high risk patients.
Key wordshypercoagulability thromboembolism fibrinopeptide A chemotherapy x surgery
Unable to display preview. Download preview PDF.
- 1.TrousseauA: Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. JB Balliere et Fils, Paris, vol 3, pp 654–712, 1865Google Scholar
- 2.RicklesFR, EdwardsRL: Leukocytes and tumor cells in thrombosis. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW (eds) Hemostasis and thrombosis, 3rd Edition. J.B. Lippincott Co, Philadelphia, 1992, in pressGoogle Scholar
- 3.RicklesFR, HancockWW, EdwardsRL, ZacharskiLR: Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Sem Thromb Hem 14: 88–94, 1988Google Scholar
- 9.WajimaT, MukhopadhyayP: Serial coagulation profiles in patients with small cell carcinoma of the lung. Thromb Haemostas Suppl 62: 136, 1989 (Abstract)Google Scholar
- 10.ZacharskiLR, MoritzTE, BaczekLA, RicklesFR EdwardsRL, FormanWB, ForcierRJ, CornellCJ, HaakensonCM, BallardHS, CrumED, JohnsonGJ, LevineJ, HongWK, O'DonnellJF, SchilskyRL, RingenbergQS, RobertF, SpauldingMB, TornyosK, WilliamsC, ZuckerS, FaulknerCS, EatonWL, HoppelCL: Effect of Mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Nat Ca Instit 80: 90–97, 1988Google Scholar
- 13.YodaY, AbeT: Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemostas 46: 706–709, 1981Google Scholar
- 19.NandS, FisherSG, SalgiaR, FisherRI: Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 12: 1998–2003, 1987Google Scholar
- 22.GadducciA, BaicchiU, delBravoB: The assessment of the hemostasis system in patients with ovarian and cervical carcinoma. The Cancer J 4: 183–187, 1991Google Scholar
- 25.BickRL: Disseminated intravascular coagulation and related syndromes: a clinical review. Sem Thromb Hem 14: 65–81, 1988Google Scholar
- 27.HoneggerH, AndersonN, HewittLA, TullisJL: Antithrombin III profiles in malignancy, relationship to primary tumors and metastatic sites. Thromb Haem 46: 500–503, 1981Google Scholar
- 28.RodeghieroF, MannucciPM, ViganoS, BarbuiT, GugliottaL, CortellaroM, DiniE: Liver dysfunction rather than intravascular coagulations as the main cause of low protein C and antithrombin III in acute leukemia. Blood 63: 969–969, 1984Google Scholar
- 31.Falanga A, Levine M, Edwards RL, Moritz TE, Zacharski LR, Rickles FR: Clotting studies in cancer patients. Report from the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. In preparation, 1992Google Scholar
- 32.EdwardsRL, MorganDL, RicklesFR: Animal tumor procoagulants: Resistry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haem 63: 133–138, 1990; Edwards RL, Silver J, Rickles FR: Human tumor procoagulants. Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Subcommittee, International Society on Thrombosis and Haemostasis. Thromb Haem, Submitted for PublicationGoogle Scholar
- 33.EdwardsRL, RicklesFR: The role of leukocytes in the activation of blood coagulation. Sem Hematol 29: 202–212, 1992Google Scholar
- 36.KubotaT, AndohK, SadakataH, TanakaH, KobayashiN: Tissue factor released from leukemic cells. Thromb Haem 65: 59–63, 1991Google Scholar
- 38.DonatiMB, FalangaA, ConsonniR, AlessioG, BassanR, BuelliM, BorinL, CataniL, PoglianiE, GugliottaL, MaseraG, BarbuiT: Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haem 64: 11–16, 1990Google Scholar
- 39.CozzolinoF, TorciaM, MilianiA, CarossinoAM, GiordaniR, CinottiS, FilimbertiE, SaccardiR, BernabeiP, GuidiG, DiGuglielmoR, PistoiaV, FerrariniM, NawrothPP, SternD: Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 84: 240–250, 1988PubMedGoogle Scholar
- 44.SalzmanEW, HirshJ: Prevention of venous thromboembolism In: ColmanRW, HirshJ, MarderVJ, SalzmanEW (eds) Hemostasis and Thrombosis: Basic principles and clinical practice. Lippincott, Philadelphia, pp 1252–1265, 1987Google Scholar
- 49.Clarke-PearsonDL, CreasmanWT, ColemanRE, SynanIS, HinshawWM: Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 18: 222–232, 1984Google Scholar
- 52.KutnowskiM, VandendrisM, SteinbergerR, KraytmanM: Prevention of postoperative deep vein thrombosis by low dose heparin in urologic surgery. Urolog Res 5: 123–125, 1977Google Scholar
- 60.PritchardKI, PaterJ, PatersonAHJ, FineS: Thromboembolic complications related to chemotherapy. Proc Amer Soc Clin Oncol 8: 25, 1989 (Abstract)Google Scholar